3.09
Schlusskurs vom Vortag:
$2.91
Offen:
$2.95
24-Stunden-Volumen:
3.22M
Relative Volume:
0.68
Marktkapitalisierung:
$333.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-258.08M
KGV:
-1.1236
EPS:
-2.75
Netto-Cashflow:
$-202.32M
1W Leistung:
+2.32%
1M Leistung:
+4.39%
6M Leistung:
-69.47%
1J Leistung:
-83.85%
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Firmenname
Rocket Pharmaceuticals Inc
Sektor
Branche
Telefon
646-440-9100
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Vergleichen Sie RCKT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RCKT
Rocket Pharmaceuticals Inc
|
3.09 | 314.00M | 0 | -258.08M | -202.32M | -2.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
2025-05-30 | Herabstufung | Evercore ISI | Outperform → In-line |
2025-05-28 | Herabstufung | Goldman | Neutral → Sell |
2025-05-28 | Herabstufung | JP Morgan | Overweight → Neutral |
2025-05-28 | Herabstufung | Jefferies | Buy → Hold |
2025-05-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2025-05-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2025-05-27 | Herabstufung | Needham | Buy → Hold |
2025-05-27 | Herabstufung | TD Cowen | Buy → Hold |
2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
2024-12-30 | Eingeleitet | Wedbush | Outperform |
2024-12-18 | Eingeleitet | Jefferies | Buy |
2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
2024-04-02 | Eingeleitet | Goldman | Neutral |
2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-02-01 | Eingeleitet | Morgan Stanley | Overweight |
2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
2022-11-01 | Eingeleitet | BTIG Research | Buy |
2022-07-08 | Eingeleitet | Raymond James | Outperform |
2021-10-20 | Fortgesetzt | Cowen | Outperform |
2021-03-02 | Eingeleitet | Stifel | Buy |
2021-02-18 | Eingeleitet | Needham | Buy |
2020-12-16 | Eingeleitet | UBS | Buy |
2020-12-08 | Herabstufung | Oppenheimer | Outperform → Perform |
2020-07-02 | Eingeleitet | JP Morgan | Overweight |
2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
2019-11-06 | Eingeleitet | Chardan Capital Markets | Buy |
2019-09-26 | Eingeleitet | Piper Jaffray | Overweight |
2019-04-23 | Eingeleitet | Robert W. Baird | Outperform |
2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
2019-02-05 | Eingeleitet | Oppenheimer | Outperform |
2018-09-13 | Eingeleitet | Ladenburg Thalmann | Buy |
2018-07-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Trendlines Converge — Decision Point for Rocket Pharmaceuticals Inc. Equity WarrantMarket Sentiment Review & Risk Controlled Daily Plans - 선데이타임즈
XTX Topco Ltd Cuts Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Chardan Capital Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price - Defense World
Rocket Pharmaceuticals Faces Investor Lawsuit Over Fatal Gene Therapy Trial – How to Join the Case - TradingView
Deadline coming up on Aug. 11th in Lawsuit for Investors who lost - openPR.com
DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - Business Wire
DEADLINE ALERT for RCKT, TEM, and DDD: The Law Offices of - GlobeNewswire
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT)August 11, 2025 Deadline to JoinContact The Gross Law Firm - PR Newswire
Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025 - Newsfile
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - MarketScreener
Rocket Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before August 11, 2025 to Discuss Your RightsRCKT - PR Newswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Rocket Pharmaceuticals sued for securities fraud, lead plaintiff deadline Aug. 11. - AInvest
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals - Bluefield Daily Telegraph
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
Has Rocket Pharmaceuticals Inc. Equity Warrant found a price floorFree Scalable Portfolio Growth Suggestions - Newser
Is Rocket Pharmaceuticals Inc. Equity Warrant forming a reversal patternReversal Signal Prediction Based on Volume - Newser
What high frequency data says about Rocket Pharmaceuticals Inc.Weekly Gain Forecast with Momentum Indicators - Newser
Will breakout in Rocket Pharmaceuticals Inc. lead to full recoveryProfit Target Planning with Exit Confidence - Newser
Faruqi & Faruqi Reminds Rocket Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025RCKT - PR Newswire
RCKT DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class ActionRCKT - ACCESS Newswire
Rocket Pharmaceuticals Hit with Class Action Lawsuit Over Securities Fraud - AInvest
Rocket Pharmaceuticals and the Rocketing Risks in Biotech Innovation - AInvest
Faruqi & Faruqi Investigates Rocket Pharmaceuticals Securities Litigation - AInvest
Combining machine learning predictions for Rocket Pharmaceuticals Inc. Equity Warrant2-Day Signal Watch with Forecast Outcome - Newser
Should you wait for a breakout in Rocket Pharmaceuticals Inc.Profitable Trading Blueprint with Entry Zones - Newser
Custom watchlist performance reports with Rocket Pharmaceuticals Inc.Free Exit Ready Momentum Stock Watchlist - Newser
Rocket Pharmaceuticals Inc. Equity Warrant stock momentum explainedBreakout Watcher with Entry and Exit Alerts - Newser
Volume spikes in Rocket Pharmaceuticals Inc. stock – what they meanSafe Entry Screening with Data Backed Analysis - Newser
Class Action Lawsuit Filed: Rocket Pharmaceuticals, Inc. (RCKT)Join by August 11, 2025Contact Levi & Korsinsky - Stockhouse
Class Action Filed Against Rocket Pharmaceuticals, Inc. - GlobeNewswire
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors – Contact Levi & Korsinsky - Morningstar
Rocket Pharmaceuticals and the Biotech Litigation Landscape: Navigating Risks in a High-Stakes Sector - AInvest
August 11, 2025 Deadline: Join Class Action Lawsuit Against Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky - Barchart.com
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class - GlobeNewswire
Rocket Pharmaceuticals stock price target raised to $3.00 from $2.50 at Jefferies - Investing.com Canada
Rocket Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
2025-08-07 | Securities Class Action Lawsuit Filed Against Rocket Pharmaceuticals, Inc. (RCKT)Levi & Korsinsky Represents Shareholders | NDAQ:RCKT | Press Release - Stockhouse
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd - GlobeNewswire
Rocket Pharmaceuticals Announces Strategic Restructuring and Leadership Changes - TipRanks
Investors in Rocket Pharmaceuticals, Inc. Should Contact - GlobeNewswire
Rocket Pharmaceuticals, Inc. Investors: Please contact the - GlobeNewswire
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress | RCKT Stock News - GuruFocus
Rocket (RCKT) Q2 Loss Narrows 16% - Nasdaq
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
RCKT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, - GlobeNewswire
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) - GlobeNewswire
Lost Money on Rocket Pharmaceuticals, Inc.(RCKT)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - Morningstar
Tools to monitor Rocket Pharmaceuticals Inc. Equity Warrant recovery probabilityLow Drawdown Picks with Weekly Updates - Newser
Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):